BioMendics Brings New Hope for Epidermolysis Bullosa Simplex Patients as TAMES‑02 Trial Advances and JPM Week Approaches
摩根大通(US:JPM) Businesswire·2026-01-06 21:45公司动态 - BioMendics公司推进其TAMES-02临床试验，该试验针对其候选药物TolaSure™ [1] - TolaSure™是一种潜在的疾病修饰性局部疗法，适应症为单纯性大疱性表皮松解症 [1]